1 surging stock with impressive fundamentals and 2 we find risky

via StockStory
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

BBWI Cover Image

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

While momentum can be a leading indicator, it has burned many investors as it doesn’t always correlate with long-term success. All that said, here is one stock with lasting competitive advantages and two best left ignored.

Two momentum stocks to sell:

Bath and Body Works (BBWI)

One-Month Return: +28.4%

Spun off from L Brands in 2020, Bath & Body Works (NYSE:BBWI) is a personal care and home fragrance retailer where consumers can find specialty shower gels, scented candles for the home, and lotions.

Why Are We Wary of BBWI?

  1. Lagging same-store sales over the past two years suggest it might have to change its pricing and marketing strategy to stimulate demand
  2. Estimated sales for the next 12 months are flat and imply a softer demand environment
  3. Earnings growth underperformed the sector average over the last three years as its EPS grew by just 3.8% annually

At $20.78 per share, Bath and Body Works trades at 8.4x forward P/E. Check out our free in-depth research report to learn more about why BBWI doesn’t pass our bar.

Trupanion (TRUP)

One-Month Return: +26.1%

Born from a vision to help pet owners avoid economic euthanasia when faced with expensive veterinary bills, Trupanion (NASDAQ:TRUP) provides medical insurance for cats and dogs through data-driven, vertically-integrated products priced specifically for each pet's unique characteristics.

Why Does TRUP Fall Short?

  1. Annual book value per share growth of 2.4% over the last five years was below our standards for the insurance sector
  2. Estimated book value per share growth of 4.1% for the next 12 months implies profitability will slow from its two-year trend
  3. Push for growth has led to negative returns on capital, signaling value destruction

Trupanion’s stock price of $29.35 implies a valuation ratio of 3.1x forward P/B. Dive into our free research report to see why there are better opportunities than TRUP.

One momentum stock to buy:

APA Corporation (APA)

One-Month Return: +22.7%

Operating in three continents with a history stretching back to 1954, APA Corporation (NASDAQ:APA) explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the U.S., Egypt, and the U.K. North Sea.

Why Are We Bullish on APA?

  1. Offerings and unique value proposition resonate with customers, as seen in its above-market 4.9% annual sales growth over the last ten years
  2. Dominant market position is represented by its $8.37 billion in revenue and gives it fixed cost leverage when sales grow
  3. Highly-profitable operating model results in strong unit economics and a top-tier gross margin of 67.7%

APA Corporation is trading at $51.96 per share, or 8.1x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.

High-quality stocks for all market conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article